Comparative Pharmacology
Head-to-head clinical analysis: EMPAVELI versus ZILBRYSQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMPAVELI versus ZILBRYSQ.
EMPAVELI vs ZILBRYSQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pegcetacoplan is a complement C3 inhibitor that binds to complement component C3 and its activation fragment C3b, thereby regulating the cleavage of C3 and the generation of downstream effectors of complement activation.
Zilbrysq (zilucoplan) is a complement component 5 (C5) inhibitor. It binds to C5 with high affinity, preventing its cleavage into C5a and C5b and thereby inhibiting the terminal complement pathway, including the formation of the membrane attack complex (MAC).
1080 mg subcutaneously once weekly for 2 weeks, then 1080 mg subcutaneously every 2 weeks thereafter.
Subcutaneous administration of 32 mg three times per week.
None Documented
None Documented
Terminal elimination half-life is approximately 7-10 days. This supports once-weekly subcutaneous dosing, achieving steady-state concentrations after 3-4 weeks of weekly administration.
Terminal elimination half-life is approximately 40 days, supporting a monthly subcutaneous dosing interval.
Primarily excreted unchanged in urine (approximately 60-70% of administered dose) and feces (approximately 20-30% as parent drug and metabolites). Less than 1% is recovered as metabolites.
Renal: approximately 70% as unchanged drug; fecal: approximately 30% as unchanged drug and metabolites.
Category C
Category C
Complement Inhibitor
Complement Inhibitor